Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug

Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug ‘Xafty’.